Literature DB >> 15145907

Diabetes: preventing coronary heart disease in a high risk group.

M D Feher1.   

Abstract

Cardiovascular disease is the major cause of morbidity and mortality in patients with type 2 diabetes. Numerous outcome trials have demonstrated clinical benefits from effective treatment of individual cardiovascular risk factors in patients with diabetes. These trials have provided the basis for current treatment guidelines and targets. More recently, multifactorial intervention strategies have shown a reduction in both cardiovascular and microvascular events in patients with type 2 diabetes. However, full implementation of a truly multifactorial strategy into routine practice remains an ideal due to practical difficulties of sustained implementation and associated costs. These practical issues relating to the treatment of diabetes and its complications are now in a greater spotlight due to the growing number of patients requiring treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15145907      PMCID: PMC1876314          DOI: 10.1136/hrt.2004.037572

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  16 in total

1.  Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

Authors:  S M Haffner; C M Alexander; T J Cook; S J Boccuzzi; T A Musliner; T R Pedersen; J Kjekshus; K Pyörälä
Journal:  Arch Intern Med       Date:  1999 Dec 13-27

2.  Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.

Authors:  X R Pan; G W Li; Y H Hu; J X Wang; W Y Yang; Z X An; Z X Hu; J Lin; J Z Xiao; H B Cao; P A Liu; X G Jiang; Y Y Jiang; J P Wang; H Zheng; H Zhang; P H Bennett; B V Howard
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

3.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

Authors:  J Tuomilehto; J Lindström; J G Eriksson; T T Valle; H Hämäläinen; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Laakso; A Louheranta; M Rastas; V Salminen; M Uusitupa
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

4.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.

Authors:  Patrick W J C Serruys; Pim de Feyter; Carlos Macaya; Norbert Kokott; Jacques Puel; Matthias Vrolix; Angelo Branzi; Marcelo C Bertolami; Graham Jackson; Bradley Strauss; Bernhard Meier
Journal:  JAMA       Date:  2002-06-26       Impact factor: 56.272

5.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

6.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

7.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

Review 8.  Diabetes: can we stop the time bomb?

Authors:  M Fisher
Journal:  Heart       Date:  2003-05       Impact factor: 5.994

9.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

Authors:  Rory Collins; Jane Armitage; Sarah Parish; Peter Sleigh; Richard Peto
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

10.  Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

Authors:  K Pyŏrälä; T R Pedersen; J Kjekshus; O Faergeman; A G Olsson; G Thorgeirsson
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

View more
  3 in total

1.  Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes.

Authors:  T H Schindler; A D Facta; J O Prior; J Cadenas; W A Hsueh; M J Quinones; H R Schelbert
Journal:  Heart       Date:  2006-08-29       Impact factor: 5.994

2.  An intensive nurse-led, multi-interventional clinic is more successful in achieving vascular risk reduction targets than standard diabetes care.

Authors:  J MacMahon Tone; A Agha; M Sherlock; F Finucane; W Tormey; C J Thompson
Journal:  Ir J Med Sci       Date:  2009-04-15       Impact factor: 1.568

3.  Prevalence and pattern of dyslipidemia in hyperglycemic patients and its associated factors among Pakistani population.

Authors:  Maliha Sarfraz; Sanaullah Sajid; Muhammad Aqeel Ashraf
Journal:  Saudi J Biol Sci       Date:  2016-03-10       Impact factor: 4.219

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.